Urology Associates Medical Group

Urology Associates Medical Group is a specialized medical practice and clinical research center located in Burbank, California. The group is distinguished by its dual focus on providing high-quality urological care and advancing the field through clinical research. It has played a critical role in the development of novel therapies, most notably serving as a primary site for the Phase 2 and Phase 3 trials of Xiaflex (collagenase clostridium histolyticum) for the treatment of Peyronie's disease. Led by Dr. Martin K. Gelbard, a recognized expert in reconstructive urology and sexual medicine, the practice offers comprehensive services for conditions such as prostate cancer, bladder disorders, and kidney stones. Currently part of the Optum network, the group leverages its research expertise to provide patients with access to the latest medical advancements in urology.